Ophthalmology Times

Ophthalmology Times Cutting-Edge Advancements
Twitter.com/OphthTimes Posting Policy:
Thank you for liking the official Ophthalmology Times page. We're glad you're here.

We are committed to creating a community that encourages self-expression and mirrors the values of Ophthalmology Times including respect for the rights, dignity, and property of others. We ask all fans to do their part to help us achieve the goal. In doing that, we ask you not to post content that:
-is threatening, abusive, obscene, indecent, or objectionable.
-is deceptive, false, or misleading
-violates the intellectual property rights of other people
-is illegal
-references a third party website or is self-promoting spam
-is inappropriate, offensive, or hateful
We reserve the right to remove any content or block users that violate our community guidelines, or that we determine are otherwise offensive to our community. All content must also comply with Facebook's policies as well.

The 0.18 fluocinolone acetonide intravitreal implant (FAi) successfully improved visual acuity, reduced macular edema (M...
02/26/2026

The 0.18 fluocinolone acetonide intravitreal implant (FAi) successfully improved visual acuity, reduced macular edema (ME), and attenuated choroidal thickening in patients with non-infectious uveitis (NIU)-associated ME during a 12-month retrospective study.

The first FAi received approval from the US Food and Drug Administration (FDA) in October of 2018 for the treatment of chronic non-infectious intermediate, posterior, or panuveitis with active inflammation. The implant is designed to release medication over 3 years; the drug is housed within a nonbioerodible material.

A recent study highlights the efficacy of the FAi implant in patients with NIU-related macular edema, improving BCVA and reducing choroidal thickness.

The authors of a new study emphasized the clear visual benefits that low-vision patients experience during low-vision re...
02/25/2026

The authors of a new study emphasized the clear visual benefits that low-vision patients experience during low-vision rehabilitation. However, they cited “substantial gaps” in the research in that there is “limited evidence of long-term outcomes, inconsistent assessment of psychosocial influences, and underrepresentation of diverse populations.”

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Dry eye disease isn’t just about artificial tears anymore. After 18 years and 13,000+ IPL treatments, Neel R. Desai, MD,...
02/24/2026

Dry eye disease isn’t just about artificial tears anymore. After 18 years and 13,000+ IPL treatments, Neel R. Desai, MD, shares how an interventional approach is transforming outcomes—especially before cataract surgery.

Interventional therapies give patients faster relief and better vision outcomes

A newly published study. describes a hypothesis that may explain how myopia is enhanced in humans. Namely, accommodative...
02/23/2026

A newly published study. describes a hypothesis that may explain how myopia is enhanced in humans. Namely, accommodative pupil constriction drives myopia progression by reducing retinal illumination.

One recent theory about the development and progression of myopia is the amount of time individuals spend engaged in using electronic screens. The current study suggests that myopia “may be driven less by screens themselves and more by a common indoor visual habit: prolonged close-up focus in low-light environments, which limits how much light reaches the retina,” according to a press release from the SUNY College of Optometry.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

New tried-and-true treatments for retinal vein occlusion: Explore latest RVO care: faricimab, Eylea HD, and biosimilars ...
02/23/2026

New tried-and-true treatments for retinal vein occlusion: Explore latest RVO care: faricimab, Eylea HD, and biosimilars that cut injection burden and protect vision from macular edema.

Explore latest RVO care: faricimab, Eylea HD, and biosimilars that cut injection burden and protect vision from macular edema.

Samsung Bioepis has entered into settlement and license agreements with Regeneron—and separately with Regeneron and Baye...
02/22/2026

Samsung Bioepis has entered into settlement and license agreements with Regeneron—and separately with Regeneron and Bayer—clearing a path for commercialization of its aflibercept biosimilar across the United States, Europe, and other global markets. Under the US agreement, OPUVIZ (aflibercept-yszy), a biosimilar to Eylea (aflibercept) 2 mg, may launch in January 2027. A separate ex-US settlement enables launch in the United Kingdom beginning January 2026, in the rest of Europe from April 2026, and in other settled markets (excluding Korea) from May 2026.

Under the US agreement, OPUVIZ (aflibercept-yszy), a biosimilar to Eylea (aflibercept) 2 mg, may launch in January 2027.

At Envision Summit 2026, the “Fast and Fundus” retina panel delivered rapid-fire case discussions grounded in practical ...
02/21/2026

At Envision Summit 2026, the “Fast and Fundus” retina panel delivered rapid-fire case discussions grounded in practical decision-making. Moderated by Maria Berrocal, MD, the session moved from anterior segment masqueraders to retinal detachment strategy, proliferative diabetic retinopathy (PDR), symptomatic floaters, and geographic atrophy—each case highlighting how anatomy, vitreous status, and real-world patient factors drive management. The discussion repeatedly returned to one central theme: treat the patient in front of you, not just the pathology.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the tr...
02/21/2026

Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the treatment of wet age-related macular degeneration (AMD).

SOL-1 (NCT06223958) is a multi-center, double-masked, randomized (1:1), parallel-group trial involving more than 100 clinical trial sites located in the US and Argentina. As reported earlier, the trial completed randomization of 344 evaluable treatment-naïve subjects with a diagnosis of wet AMD in the study eye in December 2024. The primary endpoint is the proportion of patients who maintain visual acuity, defined as a loss of

The superiority primary endpoint at week 36 was met with high statistical significance, and AXPAXLI showed either statistical significance or numerical superiority to aflibercept (2 mg) in key secondary and prespecified exploratory endpoints.

Sickle cell disease (SCD) is a serious inherited disorder that affects millions of people of African, Mediterranean, and...
02/20/2026

Sickle cell disease (SCD) is a serious inherited disorder that affects millions of people of African, Mediterranean, and Middle Eastern descent.

Two specialists—Mary Ellen Hoehn, MD, professor of ophthalmology in the Department of Ophthalmology at Hamilton Eye Institute at the University of Tennessee Health Science Center in Memphis, and Adrienne W. Scott, MD, from the Retina Division at Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland—discussed the clinical diagnosis, manifestations, and treatment of the disease with an eye toward the contributions of ophthalmologists and optometrists to patient care and with particular emphasis on its effects in women.

Clinicians emphasize screening, individualized care, and recognition of sex-based differences to prevent vision-threatening complications

In this Q&A article with the Eye Care Network, Daniela Ferrara, MD, PhD, FASRS, FARVO, discusses the role of low- and mi...
02/20/2026

In this Q&A article with the Eye Care Network, Daniela Ferrara, MD, PhD, FASRS, FARVO, discusses the role of low- and middle-income country (LMIC) data in informing US ophthalmology clinical trials, the operational and ethical considerations involved, and how artificial intelligence (AI) may help harmonize global datasets in the years ahead.

Daniela Ferrara, MD, PhD, FASRS, FARVO, discusses how data from low- and middle-income countries can strengthen US trials, improve equity, and inform innovation as the field looks toward 2026.

At Envision Summit 2026 in Rio Grande, Puerto Rico February 12-16, leaders in cornea, retina, cataract surgery, and clin...
02/19/2026

At Envision Summit 2026 in Rio Grande, Puerto Rico February 12-16, leaders in cornea, retina, cataract surgery, and clinical research convened to examine how artificial intelligence (AI) is reshaping ophthalmic care, from refractive screening and intraocular lens (IOL) calculations to diabetic retinopathy (DR) screening and AI-driven clinical trials. Across sessions, speakers emphasized that AI is not a replacement for physician judgment, but a tool to enhance precision, efficiency, and scalability.

Across sessions, speakers emphasized that AI is not a replacement for physician judgment.

Ophthalmologists continue to emphasize the importance of individualized decision-making when selecting IOLs. In an inter...
02/19/2026

Ophthalmologists continue to emphasize the importance of individualized decision-making when selecting IOLs. In an interview with Ophthalmology Times (OT), Haroon Ilyas, MD, a cornea specialist at Brandon Eye Associates in Tampa, Florida, described key highlights from OT's Case-Based Roundtable® on IOL selection in which he participated. Factors discussed included patients’ lifestyle needs, visual demands, ocular characteristics that influence IOL selection, and reported patient outcomes.

Clear counseling and tailored lens choice reduce postoperative dissatisfaction

Address

25115 Country Club Boulevard
North Olmsted, OH
44070

Telephone

(440) 243-8100

Website

Alerts

Be the first to know and let us send you an email when Ophthalmology Times posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Ophthalmology Times:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category